IPP Bureau
Pfizer posts Q3 loss as Covid-19 revenues shrink
By IPP Bureau - November 01, 2023
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Aragen setting up a US$ 30 million bio-manufacturing site in Bengaluru
By IPP Bureau - October 31, 2023
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Indian Health Minister Dr. Mandaviya addresses 76th session of the WHO Regional Committee for South-East Asia
By IPP Bureau - October 31, 2023
India is following a holistic and inclusive approach in alignment with the vison of Universal Health Coverage and the resolute commitment to ‘leave no one behind
Sun Pharma to co-market Zydus’s CKD treatment drug ‘Desidustat’ in India
By IPP Bureau - October 31, 2023
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
Alkem ‘Healthy Lungs' initiative aims to clear the air
By IPP Bureau - October 31, 2023
The initiative will focus on advocating for cleaner air
Lubrizol launches carbopol polymers for nutraceuticals with new EU good grade approval
By IPP Bureau - October 31, 2023
The European Commission approved the use of Carbopol as an additive for liquid and solid food supplements in the EU
SN Bioscience announces Phase 1 study results of SN-38 nanoparticle anti-cancer drug
By IPP Bureau - October 30, 2023
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
EnginZyme produces key mRNA vaccine ingredient using biocatalysis
By IPP Bureau - October 30, 2023
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
Tanaka develops first high entropy precious metals alloy powder
By IPP Bureau - October 30, 2023
With the establishment of five different precious metals alloy powder production methods
Dr Reddy's Q2 FY24 PAT jumps 33% to Rs 1,480 Cr
By IPP Bureau - October 30, 2023
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
Pfizer and BioNTech announce data for mRNA-based vaccine program for influenza and COVID-19
By IPP Bureau - October 30, 2023
The companies plan to start a pivotal Phase 3 trial in the coming months
Mandaviya inaugurates Rural Health Training Centre (RHTC) Hospital in Najafgarh, Delhi
By IPP Bureau - October 26, 2023
RHTC will address a long-standing healthcare access issue for all the local population
Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-mutant advanced non-small cell lung cancer
By IPP Bureau - October 26, 2023
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
USFDA accepts for review AstraZeneca’s supplemental biologics license application for self-administration of FluMist Quadrivalent
By IPP Bureau - October 26, 2023
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
Venus Remedies earns REO Certification from CII for second consecutive year
By IPP Bureau - October 26, 2023
The Responsible Export Organisation (REO) certification is a distinguished recognition awarded by the Confederation of Indian Industry (CII)
